

Torbjörn Gröslund

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4977002/publications.pdf>

Version: 2024-02-01

15
papers

164
citations

1307594

7
h-index

1125743

13
g-index

15
all docs

15
docs citations

15
times ranked

242
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2. <i>Pharmaceutics</i> , 2022, 14, 522.	4.5	2
2	Proof-of-Concept of Continuous Transfection for Adeno-Associated Virus Production in Microcarrier-Based Culture. <i>Processes</i> , 2022, 10, 515.	2.8	3
3	Identification of four novel T cell autoantigens and personal autoreactive profiles in multiple sclerosis. <i>Science Advances</i> , 2022, 8, eabn1823.	10.3	17
4	Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules. <i>Biomedicines</i> , 2022, 10, 1293.	3.2	2
5	Preclinical Evaluation of a New Format of ⁶⁸ Ga- and ¹¹¹ In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT. <i>Pharmaceutics</i> , 2022, 14, 1475.	4.5	4
6	Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution. <i>Pharmaceutics</i> , 2021, 13, 430.	4.5	8
7	Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPIn Ec1. <i>Cancers</i> , 2021, 13, 3589.	3.7	7
8	Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model. <i>Cancers</i> , 2021, 13, 3939.	3.7	8
9	Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model. <i>Cancers</i> , 2021, 13, 85.	3.7	16
10	Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein. <i>Pharmaceutics</i> , 2021, 13, 1847.	4.5	4
11	The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy. <i>Pharmaceutics</i> , 2021, 13, 1974.	4.5	6
12	HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution. <i>Pharmaceutics</i> , 2020, 12, 391.	4.5	7
13	An in vivo half-life extended prolactin receptor antagonist can prevent STAT5 phosphorylation. <i>PLoS ONE</i> , 2019, 14, e0215831.	2.5	8
14	In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor. <i>Scientific Reports</i> , 2018, 8, 5141.	3.3	32
15	Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors. <i>Journal of Controlled Release</i> , 2018, 288, 84-95.	9.9	40